The #1 Source for Information on Lobular Breast Cancer
LBCA’s Mission: To make all who are touched by ILC aware of its unique characteristics and the critical need for more ILC research; to be the go-to source for information on ILC studies, clinical trials and educational tools; to foster partnerships among patients, scientists, clinicians, and breast cancer organizations to increase dialogue about ILC and research advocacy; and to fund vital ILC research.
In the Spotlight
What's new
Research News
Education & Advocacy
My ILC Story
Jules Shares Her Story with Lobular Breast Cancer
Jules Shares Her Story with Lobular Breast Cancer
Lobular Breast Cancer Videos
Watch our videos on research and advocacy
Dr. Shannon Klingman, LUME Founder, Shares Her ILC Story and New Focus on Lobular Breast Cancer Research
Dr. Manisha Bahl Presents First LBCA ILC Guest Lectureship at Dana-Farber Cancer Institute on the Roles of 3D Imaging and AI in Improving ILC DetectionÂ
SAB Member Dr. Megan Kruse’s New Role at Cleveland Clinic Elevates Lobular Breast Cancer
The 2nd session in LBCA’s Liquid Biopsy Webinar Series Available To View On Demand
Liquid Biopsy Webinar Series – View Session 1 On-Demand
The Therapeutic Challenges of Lobular Breast Cancer – Interview with Dr. Rita Mukhtar
Living with Metastatic ILC – A Conversation with Patient Advocates
Shining a Spotlight on Lobular Breast Cancer: Spread the Word
An Update from the UK, Interview with Lobular Breast Cancer UK’s Claire Turner
Lobular Research Chat with Dr. Julia Foldi
LBCA SAB Member Dr. Rita Mukhtar Discusses New ILC Research
Meet LBCA’s Newest Scientific Advisory Board Member, Dr. Anita Mamtani from Memorial Sloan Kettering
New Metastatic ILC Patient Advocate Representative on the PAAB
Lobular Breast Cancer Chat with Dr. Randy Yeh SNMMI LBCA ILC Research Grant Winner
LBCA Partners with Memorial Sloan Kettering on New ILC Training for Radiologists & Breast Imagers!
New Lobular Breast Cancer Research Program at Dana-Farber Cancer Institute
Watch the Comprehensive Overview of Lobular Breast Cancer from Memorial Sloan Kettering
LBCA and Sarah Bieze ILC Research Grant awardee Dr. Manisha Bahl Presents Her ILC Imaging Research Study Plan
Advocate Chat with the First Recipient of the LBCA Deborah Mueller Foundation Invasive Lobular Carcinoma Research Grant, Dr. Higineo Dopeso
New Lobular Breast Cancer Program at Memorial Sloan Kettering – LBCA Interview with the Co-Directors
ILC Stories – Patients and Families Share their Stories in Video Reels
Advocate Chat with Dr. Rita Mukhtar
Shining a Spotlight on Lobular Breast Cancer on Oct.15th -During Breast Cancer Awareness Month
The American Association for Cancer Research (AACR) Interviews Julia Katherine Levine About Her Journey Living with Metastatic Lobular Breast Cancer
Hear From LBCA’s New Research Grantees About Their Winning Studies
Get to Know LBCA’s Newest Scientific Advisory Board (SAB) member, Dr. Rimawi
Hear About Latest LBCA Local Advocacy Team Activities
LBCA Lobular Breast Cancer Chat: Biomarkers as Tools in ILC
Interview with New SAB Board Member, Dr. Rebecca Shatsky
LBCA Promotes Issues on ILC and Imaging in President’s Cancer Moonshot Program
LBCA Video Takes In-Depth Look at Lobular Breast Cancer
Professional Golfer Angela Stanford Educates People About ILC
What Is Invasive Lobular Carcinoma?
Invasive lobular carcinoma (ILC), also known as lobular breast cancer, is the second most common type of breast cancer diagnosed, accounting for about 15% of all breast cancers. An estimated 48,000 new cases of ILC are diagnosed each year, impacting more women than cancers of the kidney, brain, pancreas, liver, or ovaries.Â
Research indicates that ILC is a unique histological subtype of breast cancer with distinct biological and behavioral differences.
It’s time to advance research to better understand ILC and its differences to refine treatments for patients with lobular breast disease.Â
For Patients
Access the extensive resources we have compiled for individuals with invasive lobular carcinoma (ILC) and their loved ones.
FB Groups
LBCA does not administer, moderate or review the content posted in these social media groups or the hotlines.
ILC Clinical Trials
Patients with invasive lobular carcinoma (ILC) can advance understanding of the disease by joining clinical trials. Few trials focus solely on ILC due to its lower incidence (10-15% of all breast cancers), but participation is crucial. Increased research could help improve detection, treatment, prevention of metastasis, and ultimately, develop a cure.